acute kidney injury; endothelial-to-mesenchymal transition; endothelial cilia; endothelial progenitor cells ACUTE KIDNEY INJURY (AKI) remains a fundamental problem in the field of nephrology/intensive care medicine (8, 13) . The current definition of AKI requires a rise in serum creatinine of at least 0.3 mg/dl in 48 h or a 1.5-fold rise within 7 days and/or a decrease in urine output to 0.5 ml·kg Ϫ1 ·day Ϫ1 or lower (17) . In most patients, AKI results from transient renal hypoperfusion or ischemia (ischemia-reperfusion injury). Three pathophysiological processes are fundamentally important in promoting ischemia-reperfusion injury-associated tissue damage and repair: tubular cell dysfunction/structural damage, interstitial inflammation, and peritubular microvasculopathy (10) .
Investigations performed in recent years have indicated that ischemic AKI may be treated by stem/progenitor cell-based strategies. Two cell populations especially have successfully been used in AKI: mesenchymal stem cells (MSCs) and endothelial progenitor cells (EPCs). MSCs have been administered under diverse experimental conditions and in one clinical study (6, 28, 31) . EPCs, and, in particular, early (e)EPCs [early endothelial outgrowth cells (12) ], have experimentally been used in murine ischemic AKI (7, 18 -20, 22, 23, 25, 26) . Several pharmacological strategies for eEPC preconditioning have been established in the meantime (18, 19, 22, 23, 26) , allowing a more effective preservation of kidney function shortly after ischemia. Nevertheless, the overall prognosis in AKI does not only depend on renal dysfunction in the short term but also on chronic kidney damage in the mid to long term.
Renal ischemia causes peritubular capillary rarefication and interstitial fibrosis, ultimately increasing the risk for chronic kidney disease (CKD) (1) (2) (3) (4) (5) . CKD can be diagnosed if kidney dysfunction persists for more than 3 mo and/or if, despite normal estimated glomerular filtratrion rate values ultrasound imaging reveals organ damage or urinary protein excretion is elevated for more than 12 wk (30) . The pathogenesis of postischemic fibrogenesis is complex, involving diverse cytokines and cell types (35) . Nevertheless, investigations performed by Goligorsky (14) and Zeisberg et al. (34) have suggested that interstitial fibrosis is partly being induced by the mesenchymal transdifferentiation of endothelial cells [endothelial-to-mesenchymal transition (EndoMT) (16, 34) ]. Mechanistically, transforming growth factor (TGF)-␤ plays a key role in mediating the promesenchymal switch of the cells (32) .
A new concept for the pathogenesis of EndoMT was introduced ϳ3 yr ago. A study by Egorova et al. (11) suggested that endothelial cilia are critically involved in regulating the balance between endothelial and mesenchymal cell properties. Endothelial cilia are mechanosensory organelles responsible for transducing forces of the blood flow into the cell. Individual endothelial cells typically express one primary cilium (29) . The response to different flow velocities requires cilia-mediated sensing and transduction of blood flow-associated forces in a very accurate manner. Using a nonciliated cell line, Egorova et al. (11) were able to show that a lack of endothelial cilia may promote EndoMT in a flow-dependent manner.
We therefore hypothesized that syngenic murine eEPCs protect mice from ischemic AKI not only in the short term but also in the midterm. We additionally assumed that the cells protect from postischemic fibrosis and EndoMT, possibly by modulating the endothelial ciliome.
METHODS
Animal models. The animal study protocol was in accordance with the guidelines of the German Institute of Health Guide for the Care and Use of Laboratory Animals and approved by the Institutional Animal Care and Use Committee. C57BL/6N mice were originally obtained from Jackson Labs (Bar Harbor, ME) and bred in the local animal facility of the Göttingen University Hospital. As in previous studies (18, 19, (22) (23) (24) (25) (26) , male 8-to 12-wk-old C57Bl/6N mice were used in all experiments. All animals were separately caged with a 12:12-h light-dark cycle and had free access to water and chow throughout the study.
Surgical procedures. Mice were anesthesized (300 l of 6 mg/100 g ketamine hydrochloride plus 0.77 mg/100 g xylazine hydrochloride) and placed on a heated surgical pad. Rectal temperature was maintained at 37°C. After a 1.5-cm midlaparotomy, the right kidney was removed. The left kidney was exposed, and clamping of the renal pedicle was performed with microserrefines (Fine Science Tools, Foster City, CA). For the induction of acute renal failure, we performed unilateral nephrectomy with contralateral renal pedicle clamping. The respective procedure has been used and published numerous times before (18 -20, 22-26) . It shall nevertheless be described briefly. First, a suture was placed around the right renal artery, vein, and ureter, respectively. The suture was held open until cell injection. A certain volume of eEPC-containing EBM-2 media (0.5 ϫ 10 6 eEPCs in 100 l) was injected into the right renal vein (systemic circulation). Very shortly after cell injection, the suture was closed to prevent bleeding. The kidney was removed afterward. Thirty-five or forty-five minutes before cell injection and removal of the right kidney, the left renal pedicle was transiently occluded using a vascular clamp. The vascular clamp was removed shortly after cell injection into the right renal vein (ischemia time: 35 or 45 min). The abdominal incision was closed with a 4-0 suture and surgical staples. In each experimental group, 10 animals were analyzed. Animals were euthanized at weeks 1, 4, and 6, respectively.
Culture of mouse-derived eEPCs. To perform cell injection experiments, eEPCs were isolated from C57Bl/6N mice as previously described (18, 19, (22) (23) (24) (25) (26) . Briefly, mouse mononuclear cells were enriched by density gradient centrifugation using Biocoll solution (Biochrom, Berlin, Germany) from peripheral blood and spleen cell extracts. The reason for pooling mouse mononuclear cells was to maximize the total number of cells available for injection. Immediately after isolation, mononuclear cells were mixed, and 4 ϫ 10 6 cells were plated on 24-well culture dishes coated with human fibronectin (Sigma, St. Louis, MO) and maintained in EGM-2 (Clonetics, Lonza, Walkersville, MD) supplemented with EGM Single-Quots containing 5% FCS. After 4 -5 days of culture, eEPCs were identified by the uptake of DiI-labeled acetylated low-density lipoprotein (Invitrogen, Carlsbad, CA) and binding of FITC-labeled BS-1 lectin (Sigma Diagnostics, St. Louis, MO). For in vitro cell experiments, a murine endothelial progenitor cell line was purchased (66110-37, Celprogen Stem Cell Research and Therapeutics, San Pedro, CA) and cultured according to the manufacturer's protocol.
Flow chamber analyses. Human umbilical vein endothelial cells (C-12250, PromoCell) were cultured on glass-bottom slides (10 mm, Thermo Scientific) for 48 h in EGM-2 (C-22011, PromoCell) at 37°C in 5% CO2 until slides were completely covered by a cell monolayer. Cells were exposed to a constant laminar flow (EGM-2, C-22011, PromoCell). The flow chamber was constructed in the Scientific Factory of the University of Göttingen. Flow velocity was adapted to conditions in human capillaries (0.0277 ml/s); the time of flow treatment was 3 h in each experiment. Cells were subsequently incubated with unmodified supernatant (1 ml) of native murine EPCs (66110-37, Celprogen) for either 1, 4, or 24 h. Finally, cells were stained for ␣-smooth muscle actin (␣-SMA) and ␣-tubulin. For ␣-SMA staining, rabbit anti-SMA (ab32575, Abcam) was used for primary incubation and Alexa fluor 488 goat anti-rabbit IgG (111-545-003, Jackson ImmunoResearch) was used for secondary incubation. For ␣-tubulin staining, monoclonal anti-tubulin (T6793, Sigma) was used for primary incubation and Alexa 488 goat anti-mouse (115-545-003, Jackson ImmunoResearch) was used for secondary incubation. Primary incubation was performed overnight at 4°C, whereas secondary incubation was performed for 1 h at room temperature. To visualize the nuclei, tissue sections were counterstained with 4=,6-diamidino-2-phenylindole (DAPI). Cellular abundances of ␣-SMA and ␣-tubulin were quantified using ImageJ software; cilia were identified as areas of punctually increased ␣-tubulin immunofluorescence. Some slides underwent confocal microscopy to analyze topological aspects of cellular cilium expression in a more detailed manner.
Histology including immunoflurescence of tissue sections. For the quantification of kidney fibrosis, formalin-fixated, paraffin-embedded tissue sections were stained with Masson trichrome. The amount of collagen deposition (blue area) was then semiquantitatively assessed by assigning grades of 1 (mild), 2 (moderate), or 3 (severe), as previously described (24) . To evaluate EndoMT, formalin-fixated, paraffin-embedded tissue sections were deparaffinized followed by an incubation in 3% H2O2 for 10 min. After citrate buffer treatment (microwave, 5 times for 3 min, pH 6.0), sections were stained with rat anti-mouse CD31 (platelet endothelial cell adhesion molecule-1, clone SZ31, Dianova), mouse anti-␣-tubulin (ab24610, Abcam), and rabbit anti-SMA (EMELCA) for primary incubation and with Alexa fluor 488 goat anti-rabbit IgG (Dianova), Alexa fluor 594 goat anti-rat IgG (Dianova), and Alexa fluor 488 anti-mouse IgG (Dianova) for secondary incubation, respectively. Primary incubation was performed overnight at 4°C, whereas secondary incubation was performed for 1 h at room temperature. To visualize the nuclei, tissue sections were counterstained with DAPI. Three view fields per kidney were analyzed for the colocalization of either ␣-SMA or and CD31 using ImageJ software. For collagen type I staining, deparaffinized sections were treateted with citrate buffer for 3 min (5 times) followed by blocking with 5% goat serum for 30 min (room temperature). Primary incubation was performed with rabbit anti-collagen type I (1:200, ab34710, Abcam) overnight at 4°C followed by secondary incubation with goat anti-rabbit 488 (1:400, 111-545-003, Dianova) for 1 h at room temperature. Nuclei were counterstained with DAPI. Images were analyzed using ImageJ software. Collagen type I was quantified as green immunofluorescence per cortical area.
Analysis of serum creatinine concentration. Serum creatinine concentration was measured using a commercially available kit (LT- 
RESULTS
eEPCs transiently improve postischemic serum creatinine in the midterm. Our previous studies showed significant eEPCmediated preservation of postischemic kidney function in the short term (48 h) (18 -23, 26) . We therefore aimed to investigate the midterm consequences of eEPC treatment. Ischemia was applied for either 35 or 45 min, and animals were analyzed at 1, 4, and 6 wk postischemia. Serum creatinine levels remained significantly elevated over the whole period of 6 wk under both experimental conditions (Table 1 and Fig. 1) . A single dose of native syngeneic murine eEPCs (0.5 ϫ 10 6 cells) improved creatinine levels at weeks 1 and 4. At 6 wk, creatinine levels did not differ between postischemic animals with versus without eEPC administration (35 and 45 min; Table 1 and Fig. 1) .
eEPCs reduce midterm postischemic interstitial fibrosis and modulate EndoMT. Acute renal ischemia is a risk factor for CKD. Numerous studies have revealed ischemia-induced loss of peritubular capillaries and the accumulation of connective Data are means Ϯ SE. Fibrosis is expressed in arbitrary units; the endothelial-to-mesenchymal transition (EndoMT) is expressed as percentages of endothelial (CD31-positive) cells stained positive for ␣-smooth muscle actin. P values were exclusively listed if differences were statistically significant. tissue in the interstitium (interstitial fibrosis). The latter has particularly been shown to further reduce the glomerular filtration rate in the long term (1-4). Several investigations have indicated that interstitial fibrosis partly results from the EndoMT (16, 24, 26, 32, 34) . In the present study, significant fibrosis occurred in all experimental groups without cell therapy. Systemic administration of eEPCs diminished fibrosis at all three time points with one exception (35 min, week 1) (for the exact results, see Table 2 and Fig. 2, A-D Fig. 2, E-H) .
As in previous studies (24, 26) , the EndoMT was evaluated by quantifying the expression of ␣-SMA in CD31-positive cells. Significant EndoMT occurred at week 4 (35 min) and week 6 (45 min). Early EPC administration reduced endothelial ␣-SMA abundances at both time points. The exact results and P values are shown in Table 2 and Fig. 2, I -M. 
eEPCs indirectly stabilize endothelial cilia expression and reduce EndoMT in vitro.
Altered endothelial cilia expression has been suggested as a critical event in the pathogenesis of EndoMT (11) . We therefore investigated cilia-positive endothelial cells in culture with versus without flow treatment for 3 h. In addition, we correlated cilia-positive cells with endothelial ␣-tubulin and the mesenchymal properties of the cells. To evaluate eEPC-mediated effects on endothelial cilia, ␣-tubulin, and EndoMT, cells were incubated with supernatant of native eEPCs for 1, 4, or 24 h after flow treatment, respectively. Additional confocal analysis revealed the endothelial cilium in close proximity to areas of increased ␣-tubulin density around the nucleus. To quantifiy cilia-positive cells, this particular area was therefore used for cilia identification (Fig. 3) . The results are given as percentages of counted endothelial cells displaying a primary cilium: 100 Ϯ 0% for untreated cells, 64 Ϯ 8% for cells with flow with native medium, 58 Ϯ 5.8% for cells with eEPC supernatant for 1 h (sn 1 h group), 52 Ϯ 6.2% for cell with eEPC supernatant for 4 h (sn 4 h group), and 76 Ϯ 3.5% for cells with eEPC supernatant for 24 h (sn 24 h group). The following differences were statistically significant: untreated cells vs. medium flow (P ϭ 0.008) vs. sn 1 h (P ϭ (Fig. 3) .
Cell treatment stabilizes the microvasculature and decreases intrarenal endothelial abundances of ␣-tubulin. We finally assessed peritubular capillary densities and endothelial abundances of ␣-tubulin. The latter was investigated within small arteries/arterioles. Previous studies have shown postischemic capillary rarefication as a risk factor for CKD in the long term (1-3). Capillary densities were reduced in all experimental groups without cell therapy (exception: 35 min, 1 wk). Cell administration stabilized the microvasculature after 35 min (4 wk) and after 45 min of of ischemia (1, 4, and 6 wk). The exact results and P values are shown in Table 3 and Fig. 4, A-D .
Since the in vitro data showed an association between increased percentages of cilium-positive endothelial cells with lower endothelial ␣-tubulin levels, we next analyzed ␣-tubulin expression in intrarenal endothelial cells. The special interest focused on small arteries/arterioles. In general, endothelial ␣-tubulin decreased under both experimental conditions (35 and 45 min) over time (1, 4 , and 6 wk). In addition, endothelial ␣-tubulin was lower after 45 min of ischemia at any given time point. Cell treatment further decreased endothelial ␣-tubulin after 35 min of ischemia but not after 45 min of ischemia (Table 3 and Fig. 4, E-K) .
DISCUSSION
The present study offers new insights into the mechanistical interplay between eEPCs and mature endothelial cells in ischemic AKI: serum creatinine levels did not completely normalize until week 6 postischemia. A single dose of syngeneic murine eEPCs transiently lowered creatinine levels at weeks 1 and 4, respectively. In addition, cell administration reduced fibrosis in a significant manner, and endothelial abundances of ␣-SMA were diminished at week 4 (35 min of ischemia) and week 6 (45 min of ischemia). The loss of peritubular capillaries was prevented by eEPCs over time, and endothelial ␣-tubulin was lowered in all experimental groups with the strongest decrease in eEPC-treated mice of the 45-min group. The last relevant finding was related to the dynamics of ␣-SMA and ␣-tubulin in flow-treated cultured endothelial cells: eEPC supernatant stabilized the percentages of cilia-positive cells, whereas ␣-SMA and ␣-tubulin levels decreased.
Identifying new therapeutic strategies for improving shortand long-term outcomes in AKI remains a fundamental goal in the field of renal research. Regarding the pathophysiological processes involved in ischemic AKI (10), peritubular microvasculopathy has been proposed as one possible therapeutic Peritubular capillary densities are expressed as CD31 immunofluorescence per view field (in %). Microvascular analysis was exclusively performed in tubular areas of the cortex, and glomeruli were excluded. Endothelial ␣-tubulin is expressed as percentages of endothelial (CD31-positive) cells stained positive for ␣-tubulin. P values were exclusively been listed if differences were statistically significant. target. Recently, Basile and Yoder (5) substantially reviewed the complex vascular consequences that arise upon acute renal ischemia. Among those are vasoconstriction, endothelial cell swelling, and endothelial-leukocyte interactions promoting inflammation in the short term. Nevertheless, another event that typically occurs in the postischemic period is microvascular rarefication. The latter seems to be permanent, and it may be perpetuated by local cytokine dysbalances with stronger effects of the TGF-␤ axis (5) . A study by Xavier et al. (32) revealed TGF-␤ signaling as a critical event for promoting the mesenchymal transition of endothelial cells (EndoMT) as well. Thus, the renal endothelium is significantly altered by ischemia, as reflected by vascular loss and mesenchymal transdifferentiation (5) .
The extent to which EndoMT truly contributes to postischemic kidney fibrosis remains speculative. Nevertheless, a new concept of endothelium-mediated kidney fibrosis (EndoMT) was introduced in 2011. Egorova and colleagues (11) found increased flow-induced EndoMT in nonciliated mouse embryonic endothelial cells, accompanied by Kruppel-like factor 4 downregulation. These data indicated an antifibrotic role for the endothelial ciliome. Endothelial cilia are highly specialized organelles. Under physiological circumstances, one individual endothelial cell expresses one primary cilium (29) . Cilia are responsible for transducing mechanical forces of the bloodstream (shear stress) into the cell, thus modulating cellular activity/behavior. In AKI, peritubular shear stress increases as a consequence of postischemic vascular rarefication. The longterm prognosis in AKI critically depends on vascular integrity (1, 4, 5, 14) and on interstitial fibrosis, with the latter partly being induced by the mesenchymal transition of endothelial cells (16, 24, 26, 34) . Our study is in line with the concept of Egorova and colleagues. It suggests a dynamic cascade of AKI-associated vascular rarefication, modulation of the endothelial ciliome, and EndoMT. Since our experiments showed an "inverse" association between increased percentages of cilia-positive cells and endothelial ␣-tubulin, we suppose that reduced ␣-tubulin levels mirror a process of cytoskeletal reor- ganization ultimately leading to stabilization of the endothelial ciliome. It must, however, be mentioned that even ischemia alone reduced endothelial ␣-tubulin levels in the kidney. We suggest that by redistributing ␣-tubulin to areas of cilia extrusion from the cell surface, cilia loss may be prevented. Thus, reduced ␣-tubulin after ischemia may reflect an endogenous process of self-defense that may further be stimulated by eEPCs. This idea, however, does not completely fit to the ␣-tubulin levels that were observed in the 45-min group without cell therapy. The only (very premature) conclusion that may be drawn is that the ischemia sensitivity of certain cytoskeletal components (␣-tubulin) varies depending on the duration of ischemia. These aspects must be addressed by additional studies.
The structure of the ciliary cytoskeleton has been reviewed in detail by Pederson and colleagues (27) . During the process of cilia assembly, tubulin is incorporated into the distal region of the cilium (intraflagellar transport), which substantiates our assumption that lower endothelial ␣-tubulin reflects stabilization of the cilial machinery. eEPC treatment diminished the EndoMT in the kidney and reduced endothelial ␣-tubulin as well. Thus, one may conclude that the cells are capable of acting antifibrotic via consolidating the endothelial ciliome.
Our current knowledge offers no explanation for the molecular mechanisms involved in eEPC-mediated regulation of cilia activity/assembly. Several subcellular events have been shown to modulate the length and function of cilia, including Ca 2ϩ -dependent protein kinase and MAPK activities, protein phosphatase-1, and cofilin (1) . eEPCs, on the other hand, predominantely act by indirect mechanisms. They modulate the (peri)endothelial microenvironment by secreting a diverse range of humoral factors (secretome) and by releasing vasculotrophic microvesicles (7, 15) . The latter have been documented to contain certain microRNA molecules capable to modulate endothelial and tubular cell functions (7, 9) . Nevertheless, every "molecular" idea related to eEPC-mediated modulation of the endothelial ciliome is highly speculative at the moment. The present literature offers no information at all related to the topic of "EPCs and endothelial cilia." The only conclusions that can be drawn at this stage are, first, that systemically administered eEPCs significantly stabilize cilia expression by intrarenal endothelial cells. Second, cilia stabilization paralells with reduced EndoMT. Finally, eEPCs mediate such effects by indirect mechanims. We lately finished an additional series of experiments ultimately using late EPCs. As oposed to eEPCs, late EPCs do not act indirectly but incorporate into the endothelial layer of blood vessels, thus replacing damaged endothelial cells (33) . These investigations will potentially help to futher clarify the "balanced" interplay between eEPCs and late EPCs in the process of postischemic kidney repair.
In summary, the present study supports the concept of endothelial cilia as antifibrotic organelles and indicates that eEPCs stabilize cilia integrity and function in ischemic AKI.
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